and diagnostic tests (NIV: 351; IQR: 183.88, IMV: 765.69; IQR: 851.43, p < 0.001 
INTRODUCTION
N on-invasive ventilation (NIV) is now a worldwide standard of care for hypercapnic acute respiratory failure (ARF) but its use in hypoxemic ARF is controversial, mainly because of lack of strong evidence, coming from randomized controlled trials. In the of cial European Respiratory Society/ American Thoracic Society clinical practice guidelines from 2017 the task force does not make any recommendation regarding the use of NIV on this indication [1] .
There are a lot of clinical trials regarding NIV in the acute setting. However, only a few studies with heterogeneous quality discuss pharmacoeconomical issues, most of which include only COPD patients [2] .
Hospital directors and The National Health Care Fund in Bulgaria are very concerned about health care expenditures and the amount of money spent on health care services. In the light of constant pressure for minimizing medical costs from healthcare managers all over Eastern Europe we made a cost-minimization analysis comparing IMV and NIV as treatment methods for acute hypoxemic respiratory failure.
Aim:
The main objective of our study is to estimate the direct medical costs generated by a patient on IMV and NIV during their Intensive Care Unit (ICU) stay. A secondary objective is to identify which aspect of the treatment is most expensive.
MATERIAL AND METHODS
This study includes 36 patients, requiring mechanical ventilation for de novo hypoxemic ARF due to severe pneumonia and admitted to the medical ICU of National Hospital for Pulmonary Diseases "Sv. So a" during the period 2015-2017. The diagnosis severe pneumonia was based on the criteria of the Infectious Diseases Society of America/American Thoracic Society [3] .
The two groups in our study were de ned by method of ventilation -IMV (n = 18) and NIV (n = 18). Which of the two treatment methods chosen was based on the clinicians' opinion, supported by existing NIV guidelines during the study period [4] .
Two types of data were extracted from the hospital les: information regarding the severity of the disease (FiO 2 /PaO 2 , respiratory rate and SAPS II score) and direct medical costs (for drug treatment, consumables and diagnostic tests). Costs for human resources, capital equipment, and overheads were not included, because we assumed that they were comparable for all patients as they were treated in the same ICU.
First we computed the costs for every patient and compared them by groups. Then we calculated costs per patient per day and compared them again. We observed a statistically signi cant difference in the overall costs per patient for drug treatment, consumables and diagnostic tests ( Table 1 ). The highest costs were for drug treatment -60.89% in the IMV and 61.52% in the NIV group (Fig. 1) .
The costs per patient per day were also computed and there was again a signi cant difference in all dened categories (Table 2) .
We payed special attention to antibiotics as a part of general drug treatment costs. In our sample antibiotics were 31.3% in the IMV as compared to 28.33% in the NIV group. There was no signi cant difference between the antibiotic costs per patient but it became signi cant when we made a per patient per day calculation (Table 1 and 2) .
DISCUSSION
We conducted a literature search on the pharmacoeconomy of NIV and hypoxemic ARF, and we did not nd any related articles. Most similar were several cost-effectiveness analyses of NIV for COPD exacerbations and acute cardiogenic pulmonary edema. Most of them are ICU based and compared NIV with IMV or standard therapy, but some had studied NIV in the medical ward. A clear reduction of medical costs and enhanced ef cacy was noted in all of them [5] [6] [7] [8] [9] [10] [11] [12] .
To our knowledge, we present the rst pharmacoeconomical analysis regarding patients treated with NIV and IMV for hypoxemic ARF (excluding cardiogenic pulmonary edema). We de ned three categories of direct medical costs -drug treatment (including oxygen), consumables and diagnostic tests. After conduction of statistical analysis, we found a signi cant difference between the costs in all categories between the two de ned study groups (IMV and NIV). Highest were the costs for drug treatment, around 60% of which were for antibiotics. Although we expected to see a difference in the antibiotic costs, we could not report one. Clinical trials show that NIV reduces the rate of nososcomial pneumonia and therefore the use of antibiotics [13, 14] . It is possible that we did nor encounter any statistical signi cance in this subcategory because all our patients suffered from a primary pulmonary infection and we had to use a full set of antibiotics in their treatment regimen.
Establisaling signi cant cost reduction in the NIV compared to the IMV group we also computed the costs per patient per day to avoid any bias regarding the hospital stay length. The obtained results after this second analysis remained signi cant.
A limitation of our study is that we measured only the direct medical costs and did not include human resources. In the beginning NIV can be very time consuming for the personnel [15] . But in our experience after proper training nurses spend less time for a patient on NIV, than on IMV. Another limitation of this study is the small sample size and its retrospective nature. We will continue to collect data prospectively and make another analysis to recon rm our ndings.
Conclusions:
We have shown that the direct medical costs for a patient with hypoxemic ARF on NIV are signi cantly less than those for a patient suffering the same condition and placed on IMV. This difference is maintained even after correction for the length of hospital stay of each patient (costs per patient per day). In both groups the highest costs were for drug treatment. Therefore, we can conclude that for patients with hypoxemic ARF in an ICU NIV is cheaper than IMV. 
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